{"product_id":"sentinel-lymph-node-mapping-in-thyroid-cancer-a-patients-guide-to-what-it-is-how-it-works-and-what-the-research-shows","title":"Sentinel Lymph Node Mapping in Thyroid Cancer: A Patient's Guide to What It Is, How It Works, and What the Research Shows","description":"\u003cbody\u003e\n\n\n\u003cp\u003eThis patient-friendly article explains how sentinel lymph node (SLN) mapping—a minimally-invasive technique already widely used in melanoma and breast cancer—is being applied to thyroid cancer, particularly papillary thyroid carcinoma (the most common type). For patients facing thyroid cancer surgery, this procedure helps doctors determine whether cancer has spread to lymph nodes in the neck, potentially sparing them from unnecessary removal of healthy lymph nodes. The original review article examines four main detection techniques (blue dye, radioactive tracer lymphoscintigraphy, combinations of these, and newer approaches like SPECT\/CT and nanocarbon), analyzes data from more than 40 published studies, and discusses the procedure's detection rates, benefits, and current limitations.\u003c\/p\u003e\n\n\u003ch1\u003eSentinel Lymph Node Mapping in Thyroid Cancer: A Patient's Guide to What It Is, How It Works, and What the Research Shows\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eWhat Is the Sentinel Lymph Node (and Why Does It Matter)?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#thyroid-cancer\"\u003eUnderstanding Thyroid Cancer: The Basics\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#spread\"\u003eHow Thyroid Cancer Spreads to Lymph Nodes\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#dissection\"\u003eTraditional Treatment: Neck Node Dissection and Its Risks\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#techniques\"\u003eHow Sentinel Lymph Node Mapping Works: The Four Main Techniques\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#findings\"\u003eWhat Do the Studies Show? Key Findings at a Glance\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat Does This Mean for Patients?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations: What We Still Don't Know\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations and Takeaways for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eSLN mapping is a minimally invasive way to stage papillary thyroid cancer and identify the first lymph node draining the tumor.\u003c\/li\u003e\n\u003cli\u003eUltrasound misses hidden lymph node metastases in up to 30% of thyroid cancer patients, so SLN mapping can improve staging.\u003c\/li\u003e\n\u003cli\u003eA negative sentinel node accurately predicts absence of cancer in other regional nodes, potentially avoiding unnecessary neck dissection.\u003c\/li\u003e\n\u003cli\u003eIn studies, combined lymphoscintigraphy plus blue dye showed the most consistent sentinel node detection, at 98–100%.\u003c\/li\u003e\n\u003cli\u003eThe technique's success depends heavily on surgeon experience; patients should seek care at centers with expertise in SLN mapping.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eWhat Is the Sentinel Lymph Node (and Why Does It Matter)?\u003c\/h2\u003e\n\n\u003cp\u003eThe story of the sentinel lymph node begins more than 370 years ago. In 1653, the term \u003cstrong\u003e“lymphatic”\u003c\/strong\u003e was coined by Thomas Bartholin, and since then, anatomists and physicians have worked to understand this complex system and its role in how cancer spreads through the body.\u003c\/p\u003e\n\n\u003cp\u003eIn the 1930s, the anatomist J.H. Gray made a breakthrough observation. By injecting colloidal thorium dioxide into surgical wounds, he saw that lymphatic pathways formed connections—called anastomoses—through which lymph fluid could be carried into different regional lymph nodes. His conclusion was simple but profound: the lymph nodes that drain a primary tumor are the first and most likely places where cancer will spread.\u003c\/p\u003e\n\n\u003cp\u003eIn the 1950s, Weinberg began using blue dye during operations for gastric (stomach) and lung cancer. His goal was to highlight the \"primary nodes\" draining from the tumor by turning them blue, making them easy to see. Just minutes after injection, the dye stained the lymph vessels and lymph nodes. This had a direct and immediate benefit: surgeons could avoid unnecessary node dissections.\u003c\/p\u003e\n\n\u003cp\u003eOver the next two decades, researchers refined the technique. From the 1960s, attention shifted to testicular and penile cancers, where lymphography (imaging of the lymphatic system) helped clarify how drainage from a tumor goes to a specific group of lymph nodes. Between 1965 and 1968, R.M. Cabañas performed an impressive 250 lymphograms of various tumors—including penile, testicular, breast, melanoma, anal, and rectal cancers—for his thesis in Paraguay. In 1977, he presented his findings on penile carcinoma, officially introducing the term \u003cstrong\u003e\"sentinel lymph node\" (SLN)\u003c\/strong\u003e. He concluded that the SLN's status could determine whether a complete lymph node dissection was needed.\u003c\/p\u003e\n\n\u003cp\u003eThe field took a major leap forward when Morton and colleagues published the first clinical report on SLN surgery in 223 melanoma patients in 1992. Using isosulphan blue dye, they demonstrated that a limited number of lymph nodes receiving drainage from a tumor could be identified and removed for testing.\u003c\/p\u003e\n\n\u003cp\u003eAt the \"1st International Congress on the Sentinel Node in Diagnosis and Treatment of Cancer\" in 1999, the SLN was formally defined as \u003cstrong\u003ethe first lymph node draining the lymphatic flow from a primary cancer\u003c\/strong\u003e. Since then, SLN mapping has rapidly become a standard diagnostic method for many solid tumors, including melanoma, vulvar carcinoma, penile cancer, colorectal cancer, and breast cancer.\u003c\/p\u003e\n\n\u003cp\u003eFor the SLN concept to work, three conditions must be met:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eThere must be an ordered and expected pathway of lymphatic drainage from the tumor site to the regional lymph nodes.\u003c\/li\u003e\n  \u003cli\u003eTumor cells must move sequentially through the lymphatics to a primary lymph node group.\u003c\/li\u003e\n  \u003cli\u003eThe SLN must act as a filter, trapping tumor cells from the afferent lymph flow.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe SLN procedure is a minimally-invasive diagnostic technique that carefully checks for the presence of regional lymph node metastases (cancer spread). A negative SLN accurately predicts the absence of metastases in the other regional nodes, thus avoiding unnecessary node dissection.\u003c\/p\u003e\n\n\u003cp\u003eFor thyroid cancer specifically, the first SLN study was reported in 1998 by Kelemen et al. They studied 17 patients with thyroid cancer using 1% Patent Blue V dye. The \u003cstrong\u003edetection rate (DR)\u003c\/strong\u003e—meaning the percentage of patients in whom the SLN was successfully found—was 88%, and the SLN was positive for metastases in 42% of patients. This pioneering work laid the foundation for dozens of subsequent studies.\u003c\/p\u003e\n\n\u003ch2 id=\"thyroid-cancer\"\u003eUnderstanding Thyroid Cancer: The Basics\u003c\/h2\u003e\n\n\u003cp\u003eThyroid nodules are extremely common in the general population. Their prevalence ranges from as low as 4–5% when detected by physical examination to 50–67% when detected by ultrasound or at autopsy. The good news: only about 5% of these nodules are malignant (cancerous). About 80% are colloid nodules, cysts, or thyroiditis (inflammation-related) nodes, and 10–15% are benign follicular neoplasms.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThyroid carcinoma (TC)\u003c\/strong\u003e is the most common endocrine cancer overall. It ranks as the 11th most frequent cancer of all cancers, but it is the 5th most common cancer in women. Women have a global incidence rate three to four times higher than men. The highest thyroid cancer rates have been observed in North America, Australia, New Zealand, East Asia, and Southern Europe.\u003c\/p\u003e\n\n\u003cp\u003eThe thyroid gland contains two main cell types: follicular cells and C cells (also called parafollicular cells). Understanding this distinction is important because it determines the type of cancer:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDifferentiated thyroid cancers (DTC)\u003c\/strong\u003e—including papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), and anaplastic thyroid cancer (ATC)—arise from follicular cells. Poorly differentiated thyroid cancers also originate here.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedullary thyroid carcinoma (MTC)\u003c\/strong\u003e arises from C cells.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOver 90% of thyroid cancer cases are well-differentiated DTCs. Of these, PTC accounts for about 85% and FTC for about 10–15%.\u003c\/p\u003e\n\n\u003cp\u003eSeveral risk factors increase the chance of developing DTC:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eExposure to radiation in childhood\u003c\/li\u003e\n  \u003cli\u003eAge\u003c\/li\u003e\n  \u003cli\u003eFemale gender\u003c\/li\u003e\n  \u003cli\u003eFamily history\u003c\/li\u003e\n  \u003cli\u003eHashimoto's thyroiditis (an autoimmune condition)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe age at radiation exposure matters greatly. In the first decade after the Chernobyl accident, some regions of Belarus saw a \u003cstrong\u003e100-fold rise in thyroid cancer\u003c\/strong\u003e among people who were under age 15 at the time of exposure. Additionally, epidemiological studies show that first-degree relatives (parents, siblings, children) of people with thyroid cancer have a four- to ten-fold increased risk of developing DTC themselves.\u003c\/p\u003e\n\n\u003cp\u003ePapillary thyroid cancer is classically characterized by its papillary (finger-like) appearance and distinctive nuclear features. More than 10 histological variants have been documented. It is generally considered an indolent (slow-growing) tumor, with a 30-year survival rate of over 90%. However, PTC is a \"lymphophilic\" cancer—it has a strong tendency to spread to lymph nodes. Cervical (neck) lymph node metastases are frequent and increase the probability of the disease persisting or recurring in the neck region. Tumor size, extracapsular invasion (spread beyond the thyroid capsule), and multifocality (multiple tumor foci) are all factors associated with lymph node metastases.\u003c\/p\u003e\n\n\u003cp\u003eDistant metastases (spread to other organs) are a strong predictor of poor prognosis. Among patients who die from thyroid cancer, 43–90% have distant disease. Fortunately, hematogenous (blood-borne) distant metastasis is rare: only 1–2% of PTC patients have metastases outside the neck or mediastinum at the time of diagnosis, most commonly in the lungs and bones.\u003c\/p\u003e\n\n\u003cp\u003eFollicular thyroid cancer (FTC) accounts for 10–15% of DTCs. Unlike PTC, which is typically diagnosed by cytology (cell examination), FTC is usually diagnosed at histology (tissue examination after surgery). FTC is more aggressive than the typically indolent PTC. Distant metastases, mainly in the lungs and bone, occur in 3–30% of cases, while lymph node metastases are rare.\u003c\/p\u003e\n\n\u003ch2 id=\"spread\"\u003eHow Thyroid Cancer Spreads to Lymph Nodes\u003c\/h2\u003e\n\n\u003cp\u003eThe lymphatic drainage system of the thyroid is a complex network. In PTC, the \u003cstrong\u003ecentral neck compartment\u003c\/strong\u003e is the most frequently involved site of metastatic disease, although metastases in the lateral (side) and mediastinal (chest) compartments are also common. The lymphatic channels of the thyroid capsule cross-communicate with the isthmus (the bridge of tissue connecting the two thyroid lobes) and the opposite lobe. As a result, the direction of lymphatic fluid draining through intra-thyroid capillaries is not always predictable.\u003c\/p\u003e\n\n\u003cp\u003eThe drainage patterns follow some general rules worth understanding:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eThe isthmus and the medial superior portion of the thyroid lobes usually drain through superior lymphatic vessels that rise in front of the larynx (voice box) and reach the subdigastric lymph nodes of the internal jugular chain.\u003c\/li\u003e\n  \u003cli\u003eThe media inferior lymphatics terminate in the pretracheal lymph nodes (in front of the windpipe).\u003c\/li\u003e\n  \u003cli\u003eThe lateral lymphatics drain to the superior lymph nodes of the internal jugular vein.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe data on lymph node involvement in PTC is striking:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eBetween \u003cstrong\u003e15% and 50%\u003c\/strong\u003e of PTCs have cervical lymph node metastases at diagnosis, but microscopic metastases are found in up to \u003cstrong\u003e80%\u003c\/strong\u003e of cases. The wide range reflects the different extents of neck node dissection performed in different studies.\u003c\/li\u003e\n  \u003cli\u003eMetastases occur in the central compartment (level VI)—including the pretracheal, paratracheal, perithyroidal, and precricoid nodes—in approximately \u003cstrong\u003e90%\u003c\/strong\u003e of cases.\u003c\/li\u003e\n  \u003cli\u003eMetastases in the Delphian lymph node (a node in front of the thyroid cartilage) are associated with latero-cervical (side-neck) metastases in up to \u003cstrong\u003e33%\u003c\/strong\u003e of cases.\u003c\/li\u003e\n  \u003cli\u003eThe lateral compartment is involved in between \u003cstrong\u003e51% and 100%\u003c\/strong\u003e of cases in different series. The lower jugular compartment (level IV) is the second most commonly affected site, followed by the middle (level III) and upper jugular (level II) compartments.\u003c\/li\u003e\n  \u003cli\u003eLess common are level V and VII metastases, occurring in 2–15% of cases.\u003c\/li\u003e\n  \u003cli\u003eThe contralateral (opposite side) lymph nodes are involved in up to \u003cstrong\u003e18–25%\u003c\/strong\u003e of PTC cases.\u003c\/li\u003e\n  \u003cli\u003eLateral skip metastases (where cancer bypasses the central compartment and goes directly to the lateral nodes) are found in up to \u003cstrong\u003e20%\u003c\/strong\u003e of cases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn PTCs smaller than 10 millimeters, lymph node metastases are rare and, when they occur, are generally confined to the central compartment.\u003c\/p\u003e\n\n\u003cp\u003eLymph node involvement is an unfavorable prognostic factor, particularly for disease-free survival (the length of time a patient lives without cancer recurrence), rather than for overall survival. Other principal adverse prognostic factors include male gender, age 55 years or older, tumor size larger than 3 centimeters, and extra-nodal extension (cancer spreading beyond the lymph node capsule).\u003c\/p\u003e\n\n\u003ch2 id=\"dissection\"\u003eTraditional Treatment: Neck Node Dissection and Its Risks\u003c\/h2\u003e\n\n\u003cp\u003eBecause the thyroid's lymphatic drainage network is so complicated, the direction of tumor lymphatic drainage is not always predictable during surgery. Traditional treatment for PTC with positive lymph nodes requires both total thyroidectomy (removal of the entire thyroid) and node dissection (surgical removal of lymph nodes).\u003c\/p\u003e\n\n\u003cp\u003eThe management of patients whose preoperative evaluation shows no lymph node involvement (called \u003cstrong\u003eN0 status\u003c\/strong\u003e) is a controversial issue. Given the high rate (up to 80%) of occult (hidden) micro-metastases and the resulting higher rate of locoregional persistence or recurrence in PTC, treatment approaches range from \"node picking\" (removing only suspicious nodes) to ipsilateral (one side) or radical central node dissection (CND).\u003c\/p\u003e\n\n\u003cp\u003eThis matters because \u003cstrong\u003ecentral neck dissection carries significant risks\u003c\/strong\u003e. It can damage the recurrent laryngeal nerves (RLN), which control the vocal cords, and it increases rates of hypoparathyroidism (underactive parathyroid glands, which control calcium levels). This can lead to overtreatment in patients who actually have negative lymph nodes. While some argue that the risks of CND are no greater than those of total thyroidectomy alone—especially when performed by an experienced surgeon—there is much debate about this.\u003c\/p\u003e\n\n\u003cp\u003eA 2009 review of seventeen studies involving 1,929 patients reported the following complication rates after CND:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTransient hypocalcaemia (temporary low calcium): \u003cstrong\u003e3.6–60.0%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003ePermanent hypocalcaemia: \u003cstrong\u003e0.0–14.4%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eTemporary recurrent laryngeal nerve injury: \u003cstrong\u003e0.0–25.0%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003ePermanent recurrent laryngeal nerve injury: \u003cstrong\u003e0.0–11.5%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eCurrent guidelines from the American Thyroid Association (ATA) recommend \u003cstrong\u003etherapeutic\u003c\/strong\u003e CND (removal of affected nodes) only for patients with preoperatively confirmed central lymph node metastases. \u003cstrong\u003eProphylactic\u003c\/strong\u003e CND (preventive removal) is recommended for patients without preoperative central lymph node metastases (cN0) but with advanced primary tumors (T3 or T4) or preoperative lateral lymph node metastases (cN1b), or when knowing the lymph node status is needed to plan further treatment steps. For patients with cN0 status and T1 or T2 tumors, prophylactic CND is not recommended.\u003c\/p\u003e\n\n\u003cp\u003eIt's important to note how patients are classified as cN0: through clinical examination and high-resolution neck ultrasonography (hrUS). However, hrUS can produce \u003cstrong\u003efalse-negative results in up to 30% of patients\u003c\/strong\u003e, because it simply cannot detect occult (hidden) lymph node metastases. This is precisely where sentinel lymph node mapping becomes valuable.\u003c\/p\u003e\n\n\u003ch2 id=\"techniques\"\u003eHow Sentinel Lymph Node Mapping Works: The Four Main Techniques\u003c\/h2\u003e\n\n\u003cp\u003eThe SLN procedure in PTC is an intraoperative (during-surgery) method of staging. It is used to find metastatic lymph nodes \"in and outside\" the central compartment in cN0 patients, and to identify patients who might benefit from lymph node dissection instead of prophylactic CND. Remember: the SLN is the first regional lymph node (or group of nodes) affected by metastases from a primary tumor. A negative SLN accurately predicts the lack of metastases in the other lymph nodes.\u003c\/p\u003e\n\n\u003cp\u003eFour SLN identification techniques are currently used:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eThe selective vital-dye (VD) method\u003c\/li\u003e\n  \u003cli\u003e99mTc-nanocolloid planar lymphoscintigraphy with intraoperative use of a hand-held gamma probe (LS)\u003c\/li\u003e\n  \u003cli\u003eA combination of LS and VD (LS + VD)\u003c\/li\u003e\n  \u003cli\u003e99mTc-nanocolloid planar lymphoscintigraphy with preoperative SPECT–CT and intraoperative use of a hand-held gamma probe (LS-SPECT\/CT)\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch3\u003eTechnique 1: The Vital Dye (Blue Dye) Method\u003c\/h3\u003e\n\n\u003cp\u003eThe most frequently used blue dyes are isosulphan blue, patent blue violet (V), sodium blue, and methylene blue. A literature search of PubMed (conducted by the review authors) found \u003cstrong\u003e33 papers\u003c\/strong\u003e on SLN in thyroid cancer using the blue dye method: 6 using isosulphan blue, 8 using patent blue V, and 19 using methylene blue.\u003c\/p\u003e\n\n\u003cp\u003eAmong the largest studies:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCunningham et al. (2010)\u003c\/strong\u003e examined 211 PTC patients using 1% isosulphan blue, achieving a detection rate (DR) of \u003cstrong\u003e91%\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRubello et al. (2006)\u003c\/strong\u003e used patent blue V in 153 PTC cases, with a DR of \u003cstrong\u003e69%\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMarkovic et al. (2020)\u003c\/strong\u003e used methylene blue in 153 PTC patients, with a DR of \u003cstrong\u003e91.8%\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSantrac et al.\u003c\/strong\u003e used methylene blue in 20 medullary thyroid carcinoma (MTC) patients, achieving a DR of \u003cstrong\u003e100%\u003c\/strong\u003e, with 10% positive for metastasis.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWang et al.\u003c\/strong\u003e described using indocyanine green (ICG) combined with methylene blue to detect SLNs in 45 micro-PTC patients. This approach required a longer operative time but resulted in a lower rate of hypoparathyroidism. The authors concluded that combining ICG with methylene blue is feasible, safe, and clinically significant for protecting the parathyroid glands.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMoskalenko et al.\u003c\/strong\u003e evaluated 187 patients using (for the first time) a 1% toluidine blue aqueous solution, achieving a DR of \u003cstrong\u003e97.6%\u003c\/strong\u003e, and found it no less accurate than other blue dyes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eHere's how the blue dye procedure works in practice: At surgery, the vital blue dye is injected intra- or peri-tumorally (inside or around the tumor), generally using a tuberculin syringe. The authors strongly recommend \u003cstrong\u003enot mobilizing (moving) the thyroid before injection\u003c\/strong\u003e to ensure the lymphatic drainage remains intact. The blue dye can usually be seen moving through the lymphatics to the SLN within seconds, though sometimes it takes 1–2 minutes. The blue-colored lymph nodes are then excised (removed) very cautiously to avoid removing the parathyroid glands, which can also accidentally turn blue. After dissection, the SLNs are sent to pathology for frozen section analysis (rapid microscopic examination during surgery).\u003c\/p\u003e\n\n\u003cp\u003eThe main limitations of the vital dye method include:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003ePotential disruption of the lymphatics draining the tumor\u003c\/li\u003e\n  \u003cli\u003eDifficulty identifying SLNs located outside the central compartment\u003c\/li\u003e\n  \u003cli\u003eThe risk of removing blue-stained parathyroid glands\u003c\/li\u003e\n  \u003cli\u003eThe procedure is laborious and requires experience\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch3\u003eTechnique 2: Lymphoscintigraphy with Gamma Probe (LS)\u003c\/h3\u003e\n\n\u003cp\u003eThe PubMed search found \u003cstrong\u003e14 papers\u003c\/strong\u003e on SLN in thyroid cancer using the LS method. This technique was first described by Rettenbacher et al. and was introduced to overcome some of the drawbacks of the vital dye method.\u003c\/p\u003e\n\n\u003cp\u003eKey study results:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCarcoforo et al.\u003c\/strong\u003e assessed 345 PTC patients and detected SLNs in \u003cstrong\u003e100%\u003c\/strong\u003e of them, with 22.6% positive for metastases.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKim et al.\u003c\/strong\u003e evaluated 16 MTC patients and detected SLNs by radioisotope in \u003cstrong\u003e87.5%\u003c\/strong\u003e of cases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe LS procedure works like this: Under ultrasound guidance, 99mTc-albumin nanocolloid particles are injected peri- or intra-tumorally. This radioactive tracer travels through the lymphatics, allowing the lymph vessels and SLN to be visualized on imaging. The skin projection of the SLN is then validated by external counting with a hand-held collimated gamma probe and marked with a permanent marker.\u003c\/p\u003e\n\n\u003cp\u003eAfter a varying time interval (2–24 hours), the patient is taken to the operating room. Following thyroidectomy (to avoid interference from the radioactivity of the primary tumor), the central and lateral node compartments are scanned with the hand-held gamma probe. The radioactive lymph nodes are identified, and the SLN is selectively removed. The radioactivity of the lymphatic bed is monitored to verify that the SLN dissection is complete, and the node is sent for pathology. According to the authors, SLN detection remains feasible up to 24 hours post-injection.\u003c\/p\u003e\n\n\u003cp\u003eThe LS method offers important advantages over the blue dye method:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eThe preoperative ultrasound-guided injection of radioactive particles removes the risk of damaging lymphatic vessels during surgery.\u003c\/li\u003e\n  \u003cli\u003eThe SLN can be localized both in and outside the central compartment.\u003c\/li\u003e\n  \u003cli\u003eThere is no radioactive particle uptake by the parathyroid glands.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch3\u003eTechnique 3: The Combination (LS + VD)\u003c\/h3\u003e\n\n\u003cp\u003eThe combination of lymphoscintigraphy and blue dye was first described in 6 PTC patients by Catarci et al. Two hours before surgery, patients received an intra-tumoral injection of 99mTc-labeled colloidal albumin to visualize the SLN at lymphoscintigraphy. At surgery, Patent Blue V (2.5%) was injected intra-tumorally, and the blue-stained SLN was localized using a hand-held gamma probe.\u003c\/p\u003e\n\n\u003cp\u003eThe SLN was identified in \u003cstrong\u003eall 6 cases\u003c\/strong\u003e, and the authors concluded that these two techniques have a complementary role. Other researchers who have evaluated this combination include Lee et al., Huang et al., Assadi et al., and Gelmini et al.\u003c\/p\u003e\n\n\u003ch3\u003eTechnique 4: LS-SPECT\/CT\u003c\/h3\u003e\n\n\u003cp\u003eWith this technique, the SLN is localized using a combination of 99mTc-nanocolloid planar lymphoscintigraphy, preoperative SPECT\/CT imaging (a 3D imaging technique), and intraoperative use of a hand-held gamma probe. This hybrid approach provides detailed anatomical information about the SLN's location.\u003c\/p\u003e\n\n\u003ch3\u003eNewer Techniques on the Horizon\u003c\/h3\u003e\n\n\u003cp\u003eNanotechnology has opened new possibilities. \u003cstrong\u003eNanocarbons (CN)\u003c\/strong\u003e have been used as lymph node tracers. These particles have an average diameter of 150 nanometers. When injected peritumorally, they are rapidly taken up by macrophages (immune cells), then enter the lymphatics and accumulate in the lymph nodes, staining them black.\u003c\/p\u003e\n\n\u003cp\u003eIn a 2012 study, 100 micro-PTC patients received a peritumorally injection of CN suspension. Within a few minutes, the lymphatic flow and the black-stained SLN in the central compartment were identified. The detection rate was \u003cstrong\u003e93.3%\u003c\/strong\u003e, with \u003cstrong\u003e61.1%\u003c\/strong\u003e of detected SLNs positive for metastases. Zhang et al. also examined the feasibility of combining ICG and CN injection to localize the SLN in 40 micro-PTC patients.\u003c\/p\u003e\n\n\u003cp\u003eLooking to the future, a particularly promising approach is \u003cstrong\u003e68Ga-tilmanocept PET\/CT\u003c\/strong\u003e. De Vries et al. proposed a clinical protocol using 68Ga-tilmanocept PET-CT combined with ICG-99mTc-nanocolloid in ten patients with DTC and MTC. In this protocol, patients receive a sequential ultrasound-guided injection of 68Ga-tilmanocept and ICG-99mTc-nanocolloid, followed 15–60 minutes later by 68Ga-tilmanocept PET\/CT. The next day, the SLN location is defined preoperatively using a hand-held gamma probe and marked on the skin. At surgery, the SLN is excised using the PET\/CT images, skin markings, gamma probe, and a fluorescence camera. According to the authors, this new imaging modality reduces the \"shine-through effect\" seen with the standard LS method, where radioactivity from the injection site near the tumor interferes with SLN detection. The PET\/CT better localizes the SLN even when it is close to the tumor.\u003c\/p\u003e\n\n\u003ch2 id=\"findings\"\u003eWhat Do the Studies Show? Key Findings at a Glance\u003c\/h2\u003e\n\n\u003cp\u003eTo evaluate the \"state of the art\" of the SLN method in thyroid cancer, the authors' surgical team conducted a comprehensive review in 2016. They looked at \u003cstrong\u003e41 studies\u003c\/strong\u003e on SLN detection in thyroid cancer:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e26 studies\u003c\/strong\u003e used the vital dye technique (patient numbers ranging from 9 to 300)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e12 studies\u003c\/strong\u003e used the lymphoscintigraphy technique (1 to 374 patients)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3 studies\u003c\/strong\u003e used the combination of LS + VD (6 to 45 patients)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe results showed considerable variation between techniques:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSLN visualization rates:\u003c\/strong\u003e The SLN was successfully visualized in 0–100% of cases with the vital dye method, 64–100% with the LS method, and 98–100% with the combined LS + VD method.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMetastasis positivity rates:\u003c\/strong\u003e The SLN was positive for metastases in 14–86% of cases with the vital dye method, 16–100% with the LS method, and 50–67% with the combined method.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe authors concluded that the SLN technique is feasible in thyroid cancer, but the wide ranges in these numbers highlight the heterogeneity (variability) of the techniques and study populations. The detection of the SLN in thyroid carcinoma has been described in many studies, but the role of the procedure—including its indications, results, advantages, and limits—is still debated.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat Does This Mean for Patients?\u003c\/h2\u003e\n\n\u003cp\u003eFor patients with papillary thyroid cancer, particularly those classified as cN0 (no evidence of lymph node spread on ultrasound), SLN mapping offers several potential benefits:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMore accurate staging:\u003c\/strong\u003e SLN mapping can detect metastatic lymph nodes \"in and outside\" the central neck compartment that ultrasound might miss. Remember, hrUS has a false-negative rate of up to 30%.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAvoiding unnecessary surgery:\u003c\/strong\u003e A negative SLN accurately predicts the absence of metastases in other regional lymph nodes, meaning patients with negative SLNs can avoid prophylactic central neck dissection and its associated risks—including damage to the recurrent laryngeal nerves and hypoparathyroidism.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTargeted treatment:\u003c\/strong\u003e For patients with a positive SLN, the procedure identifies who might benefit from a formal lymph node dissection instead of a \"blind\" prophylactic dissection. This allows surgeons to focus the dissection on the compartments actually at risk.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eParathyroid protection:\u003c\/strong\u003e Some techniques, such as combining ICG with methylene blue, may offer better protection of the parathyroid glands during surgery.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations: What We Still Don't Know\u003c\/h2\u003e\n\n\u003cp\u003eIt is important to understand the limitations of this review and of SLN mapping in thyroid cancer in general:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHeterogeneous techniques:\u003c\/strong\u003e The studies used different dyes, different radioactive tracers, different injection methods, and different time intervals between injection and surgery. This makes direct comparisons difficult.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWide variation in results:\u003c\/strong\u003e Detection rates ranged from 0% to 100% across studies, and positivity rates ranged from 14% to 100%. This suggests that the technique's success is highly dependent on the surgeon's experience and the specific technique used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSmall patient numbers:\u003c\/strong\u003e Many studies included fewer than 50 patients, with some as few as one patient. The largest study had 374 patients, which is modest compared to SLN studies in breast cancer or melanoma.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTechnique-specific drawbacks:\u003c\/strong\u003e The blue dye method risks staining the parathyroid glands and damaging lymphatics; the LS method suffers from the \"shine-through\" effect where radioactivity near the tumor interferes with detection.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOngoing debate:\u003c\/strong\u003e The role of SLN in thyroid cancer—with its indications, results, advantages, and limits—is still a subject of debate in the medical community.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo long-term outcome data:\u003c\/strong\u003e This review focuses on detection rates and SLN positivity, not on long-term patient outcomes such as recurrence rates or survival. Whether SLN-guided surgery improves these outcomes remains to be proven.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations and Takeaways for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on this review, here are the key takeaways for patients who may be considering or discussing SLN mapping with their care team:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about SLN mapping if you have a confirmed or suspected PTC diagnosis\u003c\/strong\u003e with no evidence of lymph node spread (cN0). The procedure may help you avoid a more extensive central neck dissection and its risks.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand that technique matters.\u003c\/strong\u003e The combined LS + VD approach showed the most consistent visualization rates (98–100%) in the review, although the newer SPECT\/CT and nanocarbon techniques also show promise. Ask your surgeon which technique they use and how experienced they are with it.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow the risks of the alternatives.\u003c\/strong\u003e If you have a prophylactic central neck dissection instead of SLN mapping, be aware that temporary low calcium affects 3.6–60% of patients, permanent low calcium affects up to 14.4%, and temporary vocal cord nerve injury affects up to 25%, according to the 2009 review of 1,929 patients.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRemember that ultrasound is not perfect.\u003c\/strong\u003e Up to 30% of patients with a \"clean\" ultrasound will actually have hidden lymph node metastases. SLN mapping can catch many of these.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStay informed about newer technologies.\u003c\/strong\u003e Techniques like 68Ga-tilmanocept PET\/CT and fluorescence-guided surgery with ICG are evolving rapidly and may offer even better detection with fewer side effects in the near future.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eChoose a high-volume center.\u003c\/strong\u003e The success of SLN mapping depends heavily on surgical experience. Because the procedure is laborious and requires skill, patients should seek care at centers with demonstrated expertise in this technique.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eIn summary, sentinel lymph node mapping is a valuable, minimally-invasive tool that is increasingly being applied to thyroid cancer surgery. It offers the possibility of more accurate staging, fewer unnecessary operations, and better protection of vital structures in the neck. While the optimal technique and its exact role are still evolving, the evidence to date supports its use in carefully selected patients with papillary thyroid carcinoma.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is sentinel lymph node (SLN) mapping for thyroid cancer?\u003c\/h3\u003e\n\u003cp\u003eSLN mapping is a minimally invasive technique used during thyroid cancer surgery to find the first lymph node that drains fluid from the tumor. This sentinel node is removed and tested for cancer. If it is negative, other neck nodes are likely cancer-free, helping avoid removal of healthy lymph nodes.\u003c\/p\u003e\n\u003ch3\u003eWho might be a candidate for sentinel lymph node mapping?\u003c\/h3\u003e\n\u003cp\u003eThe procedure is mainly for people with papillary thyroid cancer, the most common type, especially when ultrasound shows no lymph node spread, called cN0 status. Because ultrasound can miss hidden metastases in up to 30% of patients, SLN mapping can provide more accurate staging in these cases.\u003c\/p\u003e\n\u003ch3\u003eHow is sentinel lymph node mapping performed?\u003c\/h3\u003e\n\u003cp\u003eDuring surgery, a blue dye, a radioactive tracer, or both are injected into or around the thyroid tumor. The tracer travels through lymphatic vessels to the sentinel node, which is then located using a gamma probe or by its blue color. The node is removed and examined under a microscope during the operation.\u003c\/p\u003e\n\u003ch3\u003eWhat are the possible risks or side effects?\u003c\/h3\u003e\n\u003cp\u003eSLN mapping itself is minimally invasive, but if the sentinel node is positive, a more extensive neck dissection may be needed. That surgery carries risks including temporary or permanent low calcium and injury to nerves controlling the vocal cords. Some blue dye methods can stain parathyroid glands, while radioactive tracer methods may have a 'shine-through' effect.\u003c\/p\u003e\n\u003ch3\u003eHow accurate is sentinel lymph node mapping in thyroid cancer?\u003c\/h3\u003e\n\u003cp\u003eAccuracy varies widely by technique. In published studies, detection rates ranged from 0–100% with blue dye, 64–100% with lymphoscintigraphy, and 98–100% with the combined method. Sentinel node positivity for cancer ranged from 14–86% depending on the study and patient group. Success depends on surgeon experience and technique.\u003c\/p\u003e\n\u003ch3\u003eCan SLN mapping help me avoid a full neck dissection?\u003c\/h3\u003e\n\u003cp\u003eIf your sentinel node is negative, it accurately predicts that other lymph nodes do not contain cancer, so a preventive central neck dissection can be avoided. If the sentinel node is positive, your surgeon may perform a formal lymph node dissection to remove affected nodes. SLN mapping helps target only the nodes that need removal.\u003c\/p\u003e\n\u003ch3\u003eWhat should I ask my surgeon about sentinel lymph node mapping?\u003c\/h3\u003e\n\u003cp\u003eAsk whether SLN mapping is appropriate for your type and stage of thyroid cancer, especially if you have no lymph node spread on ultrasound. Ask which technique they use, their experience with it, and whether it can help you avoid a central neck dissection. Also discuss the risks and benefits compared with standard surgery.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003eThis patient-friendly article is based on the following peer-reviewed research publication:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOriginal title:\u003c\/strong\u003e Sentinel lymph node mapping: current applications and future perspectives in thyroid carcinoma\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAuthors:\u003c\/strong\u003e Isabella Merante Boschin, Loris Bertazza, Carla Scaroni, Caterina Mian, and Maria Rosa Pelizzo\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eJournal:\u003c\/strong\u003e Frontiers in Medicine (Volume 10, Article 1231566)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePublication date:\u003c\/strong\u003e 24 October 2023\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.3389\/fmed.2023.1231566\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis article is an open-access publication distributed under the terms of the Creative Commons Attribution License (CC BY). It has been adapted into plain language for educational purposes. The original source contains full citations and references for all studies mentioned here. Always consult your physician for medical advice specific to your situation.\u003c\/p\u003e\n\n\n\u003c\/body\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47423005884572,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com.br\/products\/sentinel-lymph-node-mapping-in-thyroid-cancer-a-patients-guide-to-what-it-is-how-it-works-and-what-the-research-shows","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}